Clinical Trial for Hepatocellular Carcinoma

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)

A Phase II single-arm study conducted in participants with unresectable Hepatocellular carcinoma (HCC) eligible for embolization and not eligible for or who have declined treatment with resection and/or ablation or liver transplant.

Eligibility Requirements:

• 18 and older
• Participants with confirmed unresectable HCC
• Participants with no evidence of extrahepatic disease on any available imaging

Exclusion Criteria:

• Disease amenable to curative surgery or transplantation or curative ablation.
• Participants co-infected with HBV and HDV
• Any history of nephrotic or nephritic syndrome.
• Clinically significant (e.g., active) cardiovascular disease
• Participants with uncontrolled hypertension
• History of hepatic encephalopathy

All study participants will receive the assigned study treatment, study-related medical exams, and study-related laboratory tests at no cost. Travel assistance may be available. Further details about study support can be discussed with the study team. Learn more about this study.